- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07949058
Determining the Safety of CAR T-Cell Therapy for Lymphoma
Phase I Dose-Escalation/Expansion Study of Anti-CD19/CD22 CAR T-Cell Therapy for Relapsed/Refractory Mature B-cell Lymphoma After Prior CD19 CAR T-Cell Failure
This study seeks to determine the safety of CAR T-cell therapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This study seeks to determine the safety of CAR T-cell therapy in participants with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
When non-Hodgkin lymphoma returns (relapses) or stops responding to treatment (refractory), standard options like chemotherapy or common targeted drugs can become ineffective. This study evaluates a treatment approach called CAR T-cell therapy. CAR T-cell therapy uses a participant's own immune cells (T cells) to hunt down and fight cancer.
Participants in this study will first have their T cells collected through a process called leukapheresis, where blood is drawn, spun through a machine to filter out T cells, and the remaining blood is returned to the body. In the laboratory, these T cells are modified with a Chimeric Antigen Receptor (CAR) protein, which acts like a targeting system to help the T cells recognize two specific markers on lymphoma cells: Cluster of Differentiation 19 (CD19) and Cluster of Differentiation 22 (CD22). The modified CAR T-cells are then given back to the participant through an intravenous (IV) infusion.
The main goal of this study is to find the safest and most effective dose of anti-CD19/CD22 CAR T-cells without causing unexpected or severe side effects. The study also evaluates how the body reacts to the treatment and measures how well the therapy works at shrinking or eliminating the cancer.
Type d'étude
Inscription (Estimé)
Phase
- La phase 1
Contacts et emplacements
Coordonnées de l'étude
- Nom: Clinical Trials Intake
- Numéro de téléphone: 8557028222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
Lieux d'étude
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- The University of Chicago Medicine Comprehensive Cancer Center
-
Contact:
- Clinical Trials Intake
- Numéro de téléphone: 855-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Chercheur principal:
- Alexandra E. Rojek, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance status ≤ 2
- At least 1 measurable lesion according to the Lugano Response Criteria for Malignant Lymphoma70
- Measurable disease defined as ≥ 1 measurable nodal lesion (long axis > 1.5 cm and short axis > 1.0 cm) or ≥ 1 measurable extranodal lesion (long axis > 1.0 cm) on computed tomography (CT) or magnetic resonance imaging (MRI)
- Lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy
- Total bilirubin ≤ 2.0 mg/dL (or < 3.0 mg/dL for subjects with Gilbert's syndrome or lymphomatous infiltration of the liver)
- Alanine aminotransferase (AST) and aspartate aminotransferase (AST) ≤ 3 x upper limit of normal (ULN); or ≤ 5 x ULN if known lymphomatous infiltration of the liver
- Creatinine clearance (as estimated by Cockcroft Gault) ≥ 30 mL/min
- Adequate cardiac function as defined by left ventricular ejection fraction (LVEF) ≥ 40% as assessed by echocardiography, multigated acquisition scan (MUGA), or cardiac MRI
- Baseline oxygen saturation ≥ 92% on room air
- Adequate bone marrow function without growth factor support with short-acting G-CSF within the previous 7 days or long-acting G-CSF within the previous 14 days, and without transfusion support within 7 days prior to apheresis:
- Absolute neutrophil count (ANC) ≥ 1,000/microliter (µL)
- Absolute lymphocyte count (ALC) ≥ 100/microliter (µL)
- Platelets ≥ 50,000/microliter (µL)
- Hemoglobin ≥ 7g/dL
- Subjects must have the ability to understand and the willingness to sign a written informed consent document.
Exclusion Criteria:
- The presence of any of the following will exclude a subject from study enrollment:
- Presence of acute or extensive chronic graft versus host disease (GVHD).
- Active central nervous system or meningeal involvement by lymphoma. Subjects with untreated brain metastases/central nervous system (CNS) disease will be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Patients with a history of CNS or meningeal involvement must be in a documented remission by cerebrospinal fluid (CSF) evaluation and contrast-enhanced MRI imaging for at least 90 days prior to registration.
- History of another primary malignancy that has not been in remission for at least 2 years. The following are examples of exemptions from the 2-year limit: nonmelanoma skin cancer, definitively treated stage 1 solid tumor with low risk for recurrence, curatively treated localized prostate cancer, and cervical carcinoma in situ on biopsy or a squamous intraepithelial lesion on papanicolaou (PAP) smear, and in situ breast cancer that has been completely resected.
- HIV seropositivity.
- Subjects with uncontrolled intercurrent illness.
- Pregnant or breastfeeding women are excluded from this study because CAR T-cell therapy may be associated with the potential for teratogenic or abortifacient effects. Women of childbearing potential must have a negative serum pregnancy test. Subjects of either sex who are not willing to practice birth control from the time of consent and at least 6 months after protocol-directed CAR T-cell infusion are excluded (see Section 9.6 for contraception method). Because there is an unknown, but potential risk for adverse events in nursing infants secondary to treatment of the mother with CAR T-cells, breastfeeding should be discontinued. These potential risks may also apply to other agents used in this study.
- Serologic status reflecting active hepatitis B or C infection. Patients that are positive for hepatitis B core antibody, hepatitis B surface antigen (HBsAg), or hepatitis C antibody must have a negative polymerase chain reaction (PCR) prior to enrollment. (PCR positive patients will be excluded.)
- Presence of an active and clinically relevant CNS disorder such as epilepsy, generalized seizure disorders, paresis, aphasia, stroke, uncontrolled cerebrovascular disease, cerebellar disease, severe brain injuries, dementia and Parkinson's disease
- History of autoimmune disease (i.e. rheumatoid arthritis, systemic lupus erythematosus) with requirement of immunosuppressive medication within 6 months.
- Patients who have received >1 prior CAR T-cell infusion. Patients treated with multiple CAR T-cell infusions in the context of a prior prospective therapeutic clinical trial will be permitted.
- Any medical condition likely to interfere with assessment of safety or efficacy of study treatment
- History of severe immediate hypersensitivity reaction to tocilizumab, anakinra or any of the agents used in this study
- Major surgery within 28 days prior to start of lymphodepleting chemotherapy or any planned medical/surgical treatment that might interfere with the ability to comply with the study requirements.
- Patients must have a washout period of at least 2 weeks or 5 half-lives, whichever is shorter, since any prior cancer therapy, at the time the patient undergoes apheresis, except as follows:
- Treatment with alemtuzumab or bendamustine within 6 months of apheresis, or treatment with fludarabine, melphalan, or cladribine within 3 months of apheresis
- Allogeneic hematopoietic stem cell transplant within 12 weeks prior to apheresis
- Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or equivalent) within 5 days prior to apheresis. Physiologic replacement, topical, and inhaled steroids are permitted.
- Oral targeted agents, including lenalidomide and ibrutinib, are allowed if at least 3 half-lives have elapsed prior to apheresis.
- Experimental agents within 4 weeks of apheresis unless no response or disease progression is documented on the experimental therapy and at least 3 half-lives have elapsed prior to apheresis
- Radiation within 6 weeks of apheresis. Subjects must have progressive disease in irradiated lesions or have additional non-irradiated, PET-positive lesions to be eligible. Radiation to a single lesion or lesions, if additional non-irradiated PET-positive lesions are present, is allowed up to 2 weeks prior to apheresis.
- Prior cell, gene, or antibody-based therapy (approved or investigational) targeting both cluster of differentiation 19 (CD19) and cluster of differentiation 22 (CD22).
- Prior bispecific T-cell engaging antibody therapy targeting cluster of differentiation 20 (CD20), cluster of differentiation 19 (CD19), or cluster of differentiation 22 (CD22) on B-cells: a minimum of 30 days must have elapsed between the last dose of bispecific T-cell engaging antibody therapy and apheresis.
- CD19-directed CAR T-cell infusion within 12 weeks of planned apheresis.
- Prior cell, gene, or antibody-based therapy (approved or investigational) targeting both CD19 and CD22.
- Prior bispecific T-cell engaging antibody therapy targeting CD20, CD19, or CD22 on B-cells: a minimum of 30 days must have elapsed between the last dose of bispecific T-cell engaging antibody therapy and apheresis.
- CNS prophylaxis (e.g., intrathecal methotrexate): must be stopped at least 1 week prior to apheresis
- Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin-2 [IL-2]) within 6 weeks or 5 half-lives of the drug, whichever is shorter, prior to apheresis.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Non randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Dose-Finding (Dose Escalation) Group
This group is part of the dose-finding phase of the study. The goal of this phase is to find the safest and most effective dose of CAR T-cell therapy with the fewest side effects. Participants in this group will first receive lymphodepleting chemotherapy with fludarabine (30 mg/day) and cyclophosphamide (300 mg/day) daily for 3 days (given 5 to 3 days before the T-cell infusion). After completing chemotherapy, participants will receive a single infusion of CAR-positive T-cells. They will receive 1 of 4 dose levels of CAR T-Cells based on when they join the study and side effects to each dose level. Up to 18 participants will be in this group. |
Autres noms:
Fludarabine: 30 mg will be given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The fludarabine dose remains the same (30 mg) across all dose levels (Level -1 through Level 3).
Autres noms:
Cyclophosphamide: 300 mg given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The cyclophosphamide dose remains the same (300 mg) across all dose levels (Level -1 through Level 3).
Autres noms:
|
|
Expérimental: Dose Expansion Group
This group is part of the dose expansion phase of the study. The goal of this phase is to further test the dose of CAR T-cell therapy that was selected during the dose-finding phase. Participants in this group will first receive chemotherapy with fludarabine (30 mg/day) and cyclophosphamide (300 mg/day) daily for 3 days (given 5 to 3 days before the T-cell infusion). After completing chemotherapy, participants will receive a single infusion of CAR-positive T-cells at the selected dose. Up to 36 participants will be in this group. |
Autres noms:
Fludarabine: 30 mg will be given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The fludarabine dose remains the same (30 mg) across all dose levels (Level -1 through Level 3).
Autres noms:
Cyclophosphamide: 300 mg given by intravenous (IV) infusion daily for 3 days (given 5 to 3 days before T-cell infusion). Note: The cyclophosphamide dose remains the same (300 mg) across all dose levels (Level -1 through Level 3).
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safe Dose Level (Recommended Phase 2 Dose)
Délai: Day 30 after CAR T-cell infusion
|
To find the safest dose of anti-CD19/22 CAR T-cells as assessed by tracking severe side effects (dose-limiting toxicities) during the first month after treatment. |
Day 30 after CAR T-cell infusion
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Safety Profile of Anti-CD19/CD22 CAR T-cells
Délai: First day of CAR T-cell infusion (Day 0) through 12 months after infusion
|
To describe the safety profile related to the infusion of anti-CD19/CD22 CAR T-cells, evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5. |
First day of CAR T-cell infusion (Day 0) through 12 months after infusion
|
|
Severity of Toxicities Related to Treatment with Anti-CD19/CD22 CAR T-cells
Délai: First day of CAR T-Cell infusion (Day 0) through 12 months after infusion
|
To record the severity of toxicities (side effects) related to the infusion of anti-CD19/CD22 CAR T-cells, evaluated and graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5. |
First day of CAR T-Cell infusion (Day 0) through 12 months after infusion
|
|
Percentage of Participants with Overall Response Rate
Délai: Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion
|
The percentage of participants whose cancer shrinks or completely disappears (complete response) following CAR T-cell treatment as assessed by standard disease response criteria for lymphoma (PET-CT imaging and clinical response assessments). |
Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion
|
|
Percentage of Participants with Complete Response Rate
Délai: Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion
|
The percentage of participants who show a complete disappearance of all signs of cancer (complete response) following CAR T-cell treatment as assessed by standard disease response criteria for lymphoma (PET-CT imaging and clinical response assessments). |
Assessed at Day 30, Day 60, Day 90, 6 months, and 12 months post-infusion
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Alexandra E. Rojek, MD, University of Chicago
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs
- Maladies du système immunitaire
- Tumeurs par type histologique
- Maladies lymphatiques
- Troubles lymphoprolifératifs
- Troubles immunoprolifératifs
- Lymphome
- Maladies hémiques et lymphatiques
- Lymphome à cellules B
- Lymphome non hodgkinien
- Acides aminés, peptides et protéines
- Protéines
- Produits chimiques organiques
- Techniques d'investigation
- Thérapeutique
- Hydrocarbures
- Moutards phosphoramides
- Composés de moutarde d'azote
- Composés moutarde
- Hydrocarbures, halogénés
- Phosphoramides
- Composés organophosphores
- Récepteurs, surface cellulaire
- Protéines membranaires
- Thérapie biologique
- Techniques immunologiques
- Immunomodulation
- Transfert adoptif
- Immunisation, passive
- Immunisation
- Immunothérapie
- Récepteurs, immunologique
- Récepteurs, artificiels
- Récepteurs, antigène, cellules T
- Récepteurs, antigène
- Récepteurs, cytoplasmiques et nucléaires
- Cyclophosphamide
- fludarabine
- phosphate de fludarabine
- Immunothérapie, adoptive
- Récepteurs, antigène chimérique
Autres numéros d'identification d'étude
- IRB26-1043
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .